All In Biotech

Drug Trial Radar · NCT07927608

A First-in-Human Study of Phelimin in Healthy Volunteers and Adults With PKU

A Phase 1 First-in-human Study of a Phenylalanine-binding Polymer (Phelimin) in Healthy Volunteers and Adult, Classical PKU Patients.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

7

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
MipSalus ApsIndustry
Sponsor type
Industry
Collaborators
Smerud Medical Research International AS; Copenhagen University Hospital, Rigshospitalet
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human study will evaluate the safety and tolerability of phelimin, an investigational oral treatment being developed for people with phenylketonuria (PKU). Phelimin is designed to bind the amino acid phenylalanine in the gut, which may reduce its absorption from food and support its removal from the body in stool. The study will include healthy volunteers and adults with classical PKU. Participants will receive single doses of phelimin at increasing dose levels and will undergo safety assessments, including monitoring for side effects, laboratory tests, and gastrointestinal symptoms. The study will also explore whether phelimin affects blood phenylalanine levels after a standardised protein challenge.

Conditions

  • Phenylketonuria (PKU)
  • Phenylketonuria

Interventions

  • PheliminDrug

    Phelimin is an orally administered investigational medicinal product based on molecular imprinted polymer technology designed to bind phenylalanine and phenylalanine-containing oligopeptides in the GI tract, facilitating their elimination without systemic absorption.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Emergent Adverse EventsTime frame: From enrollment to 4 weeks after last dose.
  2. AEsTime frame: From enrollment to 4 weeks after last dose
  3. Serious adverse events (SAE)Time frame: From enrollment to 4 weeks after the last dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Inherited Metabolic Diseases, Rigshospitalet

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.